1. Beyond the budget silo approach: estimating health system sustainability for future dementia drugs

   L. Gozzo ¹, G. Benfatto ¹, F. Giorgianni ², J. Sultana ², E. Rossi ³, L. Longo ¹, S. Mansueto ¹, D. C. Vitale ¹, C. Savoca ⁴, F. Caraci ^5,6, M. De Rosa ³, G. Trifirò ², F. Drago ^1,4
   Opinion Paper, 68-78
   doi: 10.36118/pharmadvances.03.2020.01
   Full text PDF

2. Esketamine: the first glutamatergic drug for the management of treatment- resistant depression

   L. Musazzi
   Review, 79-86
   doi: 10.36118/pharmadvances.03.2020.02
   Full text PDF

3. From Gut to Brain: a pas de deux between oleoylethanolamide and neuronal histamine

   G. Provensi
   Review, 87-98
   doi: 10.36118/pharmadvances.03.2020.03
   Full text PDF

4. Abdominal pain: mechanisms, therapies and experimental models

   E. Lucarini, L. Di Cesare Mannelli, C. Ghelardini
   Review, 99-137
   doi: 10.36118/pharmadvances.03.2020.04
   Full text PDF

5. State of the art on clinical trials of gene therapy in haemophilia

   I. Garagiola ¹, F. Peyvandi ^1,2
   Review, 138-147
   doi: 10.36118/pharmadvances.03.2020.05
   Full text PDF